

11 December 2025

BXN Secures First-Mover Supply Agreement in Emerging Central American Cannabis Markets

- Bioxyne announces its first entry into the emerging medicinal cannabis markets of Costa Rica and Panama through a manufacturing and supply agreement with Remidose LATAM SRL
- Agreement ensures first-mover position in high-potential, low-competition Central American markets where non-flower dosage forms like pastilles are expected to dominate
- The agreement includes minimum order commitments that underpin more than A\$1 million in potential annual revenue once regulatory approvals are obtained
- This partnership supports Bioxyne's FY26 growth trajectory, targeting A\$65–75 million in revenue and A\$11.5–13.5 million EBITDA

Australian Pharmaceutical Manufacturer **Bioxyne Limited (ASX: BXN)** ("**Bioxyne**" or "**the Company**"), through its wholly owned subsidiary Breathe Life Sciences (BLS), is pleased to announce that it has entered into a Manufacturing Agreement ("agreement") with Remidose LATAM SRL ("Remidose"), a Costa Rican entity affiliated with Canadian medicinal cannabis company Remidose Aerosols Inc.

Under the agreement, BLS will manufacture pharmaceutical-grade THC pastille products for supply into the emerging medicinal cannabis markets of Costa Rica and Panama.

The agreement marks Bioxyne's first entry into the Central American medicinal cannabis market with potential for growth into South America. This leverages BLS's position as a leading Australian GMP manufacturer of pharmaceutical-grade cannabis pastilles. Remidose, a Canadian-based specialist in precision-dosed metered dose THC inhalers and transdermal topical gels, selected BLS for its reliability and consistency in producing high-quality THC pastilles.

The Costa Rican and Panamanian medicinal cannabis markets are in early stages of development, with pastille formats expected to play a significant role alongside other non-flower dosage forms.

Supply under the agreement is subject to successful TGA export approvals and relevant in-market product registrations, which the parties will progress immediately.

Chief Executive Officer Sam Watson commented:

"We are excited to announce this manufacturing and supply agreement with Remidose LATAM SRL. This partnership represents a key step in our growth trajectory, as we continue to scale globally. It aligns perfectly with Bioxyne's 'people, purpose, profits' ethos, delivering a strategic foothold in underserved markets and reinforcing our role in redefining medicine across borders."



Significance of the Bioxyne-Remidose LATAM Agreement

The manufacturing and supply agreement positions Bioxyne as a first mover in these high-potential, low-competition Central American markets. The deal could generate over A\$1 million in annual revenue once TGA export approvals and in-market registrations are secured.

Strategically, it validates Bioxyne's GMP-certified expertise as a reliable supplier of pharmaceutical-grade, non-flower formats like pastilles.

President CEO of Remedose LATAM SRL, Mr Ludwig Muller commented:

"We believe medicinal pastilles will be dominant in Latin America due to the reality that most countries are adopting GMP principles for medicinal cannabis products, including Costa Rica. We are very pleased to partner with Bioxyne to bring high quality and accurately dosed medicinal cannabis products that can help so many Costa Ricans and Panamanians."

Key commercial terms include:

Products

- Three SKUs – THC 10mg, THC: CBD 10:10mg and THC: CBD: CBN 5:5:10mg

Minimum Order Quantities

- Combined minimum of 10,000 units per quarter or 40,000 units annually across both markets

Value

- Based on indicative pricing and minimum volumes the Agreement represents potential annual revenue in excess of A\$1 million once full supply commences

Term

- Initial 12-month rolling term with automatic renewal and terminable only on 6 months' notice

Approved by the Board of Bioxyne Limited for release to the ASX.

For further information, please contact:

Bioxyne Limited

Sam Watson
Chief Executive Officer
info@bioxyne.com

NWR Communications

Melissa Tempra
Media & Investor Relations
melissa@nwrcommunications.com.au



About Bioxyne Limited

Bioxyne Limited is an Australian pharmaceutical company focused on the development and commercialisation of innovative medicines and active pharmaceutical ingredients. Through its subsidiary, Breathe Life Sciences, Bioxyne is expanding into the production of psychedelic compounds for therapeutic use.

About Breathe Life Sciences

Breathe Life Sciences (“BLS”) is a wholly owned subsidiary of Bioxyne Ltd (BXN:ASX) and GMP-licensed manufacturer, wholesaler, importer and exporter of controlled substances (S3, S4, S8, S9), including medicinal cannabis, Psilocybin, and MDMA.

BLS was founded in 2018 and has quickly expanded into a multi-national business focused on alternative therapeutics and investigational medicines. The company’s corporate head office is in Sydney, with operations and licensed manufacturing, warehousing, import/export, sales and distribution centres in Queensland (Australia), Nagoya (Japan), Manchester (UK), and Prague (Czechia).

The BLS business model is focused on manufacturing final dose form medicines, sales and distribution. BLS sources raw materials and API from suppliers in 5 continents and is the Australian market leading manufacturer of therapeutic goods including cannabis, MDMA, and Psilocybin.

Outside of Australia the BLS Group operates in pharmaceuticals, medical cannabis, consumer health products, and novel foods (CBD). In the UK, Europe and Japan, the Company engages in the following activities:

- a) Owner of Dr Watson® brand in the UK, Japan, Australia and New Zealand. Internationally recognized for its cannabis-based food supplements, health products, and prescription-only cannabis medicines.
- b) Contract drug manufacturing and white label manufacturing of scheduled medicines, therapeutic goods, medical devices, consumer health products, and active pharmaceutical ingredients. BLS manufactures over 200 of Australia’s medicinal cannabis brands.
- c) Import, export, and wholesale of active pharmaceutical ingredients, starting materials, patient-ready medicinal products, and/ or consumer health products in Australia, Japan, UK, USA and Europe.
- d) Research and development of novel medicines.
- e) Direct sales via online and wholesale of BLS-owned consumer brands, such as Dr Watson®
 - United Kingdom: drwatsoncbd.com
 - UK / EU: breathelifesciences.com

Corporate: bioxyne.com

Australia: bls.com.au

International: breathelifesciences.com